LEUKAPHERESIS DEVICES MARKET ANALYSIS

Regional Analysis

Global Leukapheresis Devices Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global leukapheresis devices market over the forecast period. North America is estimated to hold 38.3% of the market share North America holds a significant market share in the leukapheresis devices market worldwide, mainly due to the key market players are focusing on organic statergies such as launch of novel leukapheresis devices. For instance, in June 2021, OrganaBio, LLC, a biotechnology company in U.S., announced the launch of adult peripheral blood-derived products, including vialed peripheral blood mononuclear cells (PBMCs) and whole leukopaks (LeukoPAC). These products contain high concentrations of PBMCs, such as T cells, NK cells, B cells and monocytes, which are critical raw materials for immunotherapy research and allogeneic cell therapy development and manufacturing. OrganaBio’s unique supply chain and manufacturing capabilities enable it to process PBMCs within hours of collection to ensure delivery of high-quality starting material to researchers and therapeutics developers.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa